-
-
In a clinical trial of darbepoetin alfa for patients with low or intermediate risk myelodysplasia, the drug was well tolerated and resulted in improved hemoglobin levels and quality of life in a substantial proportion of patients.
-
TLK286 is an active agent in chemotherapy-resistant ovarian cancer. Further studies of TLK286 in platinum and paclitaxel refractory or resistant ovarian cancer are in progress.
-
-
-
The results of this study show that HDT intensification, when given to myeloma patients who have responded to the initial chemotherapy, significantly increases the CR rate but has no significant impact on PFS or OS.
-
Because these women are unlikely to receive depression treatment or supportive counseling, there is a need for routine screening, evaluation, and treatment in this population.
-
The FDA has approved nelarabine for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic leukemia (T-LBL). Nelarabine was approved under the FDAs accelerated approval program. It received an Orphan Designation because it is for a rare disease affecting less than 200,000 in the United States. Nelarabine is marketed by GlaxoSmithKline as Arranon®.
-
-
Researchers studying a population of HIV patients found that a pill reminder improved adherence for those who were memory impaired.
